Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Pyrocarbon-Interpositionsarthroplastik des Ellenbogens (HAPY)

4. November 2026 aktualisiert von: Wrightington, Wigan and Leigh NHS Foundation Trust

Eine prospektive Fallserie zur Bewertung der Ergebnisse und Akzeptanz einer neuartigen chirurgischen Technik der Pyrocarbon-Interpositionsarthroplastik des Ellenbogens bei jungen Patienten mit schwerer Arthritis.

The current study will be a prospective observational study (or collective case study in a small, carefully selected cohort of consenting patients with advanced arthritis. This study would be classified as a stage I study according the IDEAL framework for surgical innovation

Studienübersicht

Status

Abgeschlossen

Intervention / Behandlung

Detaillierte Beschreibung

Osteoarthritis (OA) of the elbow is associated with pain and loss of motion, which can have a dramatic impact on overall upper limb function due to the inability to position the hand to carry out activities of daily living. OA is characterised by osteophyte formation of the olecranon, coronoid and olecranon fossae, whilst the ulnohumeral and radiohumeral joint spaces may be relatively well preserved. The osteophytes cause terminal extension and flexion pain and impingement, whilst the limited arc of movement is often relatively pain-free. Loose bodies are also commonly present and can cause mechanical locking. Pain throughout the limited range of movement however, indicates joint destruction. This can be confirmed radiographically, which in contrast to the typical OA presentation described above, shows articular cartilage loss with narrowing or obliteration of the entire joint space, not usually seen in primary osteoarthritis. The pathologies in which loss of joint space is more commonly seen are post-septic arthritis, post-traumatic arthritis and inflammatory arthritis.

Total elbow arthroplasty (TEA) is thought to be an effective treatment for a range of pathologies including rheumatoid arthritis, late stage primary osteoarthritis, acute fracture and post-traumatic arthritis. However, it has been reported in the literature that younger patients undergoing TEA may experience earlier failure of the implant and higher complication rates. This is thought to be linked to higher functional demands placed on the implant due to greater occupational loading or participation in more demanding leisure activities. For this reason, other viable alternative to TEA are being sought by surgeons for younger patients with high functional demands.

Interposition arthroplasty has been proposed as an alternative to TEA for younger patients in the literature with various surgical techniques described. According to Thomas, the basic principle of interposition arthroplasty of the elbow is to perform a resection of the opposing bone ends and place something in between the distal humerus and the olecranon, which will then theoretically allow movement to occur without painful grinding of the joint.

Two of the major risks of TEA are aseptic loosening and periprosthetic infection. In the event of a significant joint infection, revision of the TEA procedure is often necessary and may be performed as a two-stage operation. Initially the prosthesis is removed and the infection is treated, a process that often involves the use of an antibiotic-impregnated spacer and oral antibiotics. If appropriate, once the infection is eradicated, a new prosthesis will be implanted. Cases have however been documented in the literature where the patients in receipt of spherical antibiotic cement spacers are satisfied with the movement and pain relief provided by the spacer, and subsequently decline re-implantation of a second prosthesis and. This has led the current author to question whether interposition arthroplasty using a spherical joint spacer may be a viable alternative to TEA in young patients with higher functional demands in whom there is a greater risk of premature aseptic loosening after TEA.

Pyrocarbon interposition implants have been successfully used in the small joints of the hand, wrist and foot, and more recently their use has been trialed in the shoulder with acceptable outcomes . Pyrocarbon is deemed an ideal material for the manufacture of orthopaedic implants due to its strength, resistance to wear and resistance to fatigue. It is also stated in the literature that there have been no reports of periarticular infiltration or reaction to pyrocarbon particles transmitted by the blood or lymphatic systems into organs such as the brain, kidneys or liver.

In the current study, we propose to perform interposition arthroplasty of the elbow using a spherical pyrocarbon implant normally used in the hand and wrist ('HAPY' pyrocarbon sphere, Wright Medical, USA), in a small case series of specially selected young patients with advanced arthritis who would otherwise require a total elbow arthroplasty.

Eligible patients attending the current author's clinic with advanced arthritis of the elbow, who are unsuitable for TEA due to their young age and high functional demands, will be invited to be part of the study. They will undergo the same pre and post-operative radiographic investigations as those undergoing TEA; A/P and lateral X-Ray views of the elbow at approximately 3 weeks, 3 months, 6 months, 12 months and 24 months. They will also complete patient reported outcome measures (PROMs) both pre-operatively, and at each of their post-operative clinic visits, as per routine practice within the host NHS Trust. Each of the PROMs to be used in this study will be a validated measure of upper limb function suitable for use in those with elbow pathology. An 11 point numerical rating scale for measurement of pain level will also be completed at each time-point in addition to goniometric measurement of elbow range of movement using a standardised technique and recording of adverse events. It is usual practice within the host NHS Trust for patients undergoing TEA to be reviewed following surgery at approximately 3 weeks, 3 months, 6 months, one year and 2 years. The same approximate follow-up schedule will be followed for patients undergoing the study procedure unless early problems are identified and there is a clinical need for more frequent follow-up assessment.

The protocol has been sent for external independent scientific review. The outcome of which has been enclosed alongside this protocol for review by the committee.

It will be made clear to all participants that pyrocarbon interposition arthroplasty of the elbow is an innovative and novel procedure and that the alternatives to this treatment would be TEA or continued conservative management. If the procedure fails to provide an acceptable outcome, the patient would then be offered a revision to a TEA. The previous interposition arthroplasty should not compromise a subsequent total elbow replacement as the bone resection is limited.

The previous literature relating to the use of spherical cement spacers in the elbow and the use of pyrocarbon interposition arthroplasty in other joints, leads us to believe that the proposed procedure in this study would prove a viable alternative for young patients with advanced arthritis of the elbow joint. However, for patient safety, a data monitoring committee will scrutinise the early data and if the complication rate is unacceptable or outcome unsatisfactory, the study will be terminated. The findings of this study, regardless of the number of participants or the success of the procedure, will be submitted for publication to further advance this field of orthopaedic practice.

The study data will be subject to internal scrutiny at 6 monthly intervals by colleagues within the upper limb unit at Wrightington, and external scrutiny by an external expert in the field.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

10

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Wigan, Vereinigtes Königreich, WN6 9EP
        • Wrightington, Wigan & Leigh Teaching Hospitals NHS Foundation Trust

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 60 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Medically fit for surgery
  • Advanced osteoarthritis, post-traumatic arthritis, or post-septic arthritis
  • Severe inflammatory arthritis without severe bone destruction - Larsen grade III or less
  • Failed conservative treatment
  • Unsuitable for TEA due to high functional demands

Exclusion Criteria:

  • Severe inflammatory arthritis with severe bone destruction
  • Arthritis suitable for treatment with arthroscopic debridement.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: HAPY interposition elbow replacement

HAPY is a pyrocarbon sphere for use as an interposition joint replacement. In this study, the implant is being used as a novel procedure in the Elbow (outside approved label usage)

A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Safety and acceptability
Zeitfenster: 24 months

The principal research objective is to assess the safety and acceptability of interposition arthroplasty of the elbow using a spherical pyrocarbon implant in a prospective consecutive case series of carefully selected patients.

24 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Motion Analysis
Zeitfenster: 24 months

Secondary Objective using motion analysis (special equipment to measure small movements and changes in elbow biomechanics) will be to quantify elbow joint Range of Movement and stability pre-operatively, and at 3- and 6-months post-operatively following interposition elbow arthroplasty and to compare this to a sex-matched group of patients after total elbow replacement.

24 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Mitarbeiter

Ermittler

  • Hauptermittler: Adam Watts, Wrightington, Wigan & Leigh Teaching Hospitals NHS Foundation Trust

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

17. Oktober 2022

Primärer Abschluss (Tatsächlich)

7. Oktober 2026

Studienabschluss (Tatsächlich)

7. Oktober 2026

Studienanmeldedaten

Zuerst eingereicht

14. Juli 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. Juli 2022

Zuerst gepostet (Tatsächlich)

19. Juli 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

9. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • HAPY

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren